Evidence map›Paper›PMID 23181971›Full record

ReviewDrugs2012

Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Guru Trikudanathan, Preethi G K Venkatesh, Udayakumar Navaneethan

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02952131 phase1 / phase2suspendednot on this mapstarted 2016, after this paper: background citation

Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

TypeinterventionalSponsorHealeon Medical IncRan2016 to 2026Enrolled100ConditionsInflammatory Bowel DiseasesArmsLipoaspiration, AD-cSVF, Normal Saline IV
NCT03799471 completednot on this mapstarted 2019, after this paper: background citation

Somatosensory Profiles in Individuals With Persistent Musculoskeletal Pain and Inflammatory Bowel Disease

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2019 to 2019Enrolled77ConditionsInflammatory Bowel Diseases, Chronic Pain, Central Sensitization
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Orbital manifestations of inflammatory bowel disease - a systematic review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Guru TrikudanathanDepartment of Internal Medicine, University of Connecticut Medical Center, Farmington, CT, USA.
Preethi G K Venkatesh
Udayakumar Navaneethan
Cleveland Clinic · USSt. Vincent Charity Hospital · USUConn Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extra-intestinal manifestations (EIMs) are reported frequently in patients with inflammatory bowel disease (IBD) and may be diagnosed before, concurrently or after the diagnosis of IBD. EIMs in IBD may be classified based on their association with IBD disease activity. The first group has a direct relationship with the activity of the bowel disease and includes pauciarticular arthritis, oral aphthous ulcers, erythema nodosum and episcleritis. The second group of EIMs appears to follow an independent course from the underlying bowel disease activity and include ankylosing spondylitis and uveitis. The third group includes EIMs that may or may not be related to intestinal inflammation, such as pyoderma gangrenosum and probably primary sclerosing cholangitis (PSC). Genetic susceptibility, aberrant self-recognition and immunopathogenic autoantibodies against organ-specific cellular antigens shared by the colon and extra-colonic organs may contribute to the pathogenesis and development of these EIMs. The use of biological agents in the IBD armamentarium has expanded the treatment options for some of the disabling EIMs and these agents form the cornerstone in managing most of the disabling EIMs. PSC is one of the most common hepatobiliary manifestations associated with IBD in which no clear treatment options exist other than endoscopic therapy and liver transplantation. Future research targeting the pathogenesis, early diagnosis and treatment of these EIMs is required.

Indexed as

Biliary Tract DiseasesEye DiseasesHematologic DiseasesHumansInflammatory Bowel DiseasesKidney DiseasesLiver DiseasesLung DiseasesMusculoskeletal DiseasesNervous System DiseasesSkin Diseases

Identifiers

PMID23181971
OpenAlexW2019593469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.